← Back to search
INTERNATIONAL AIDS VACCINE INITIATIVE INC.
Doing business as INTERNATIONAL AIDS VACCINE INITIATIVE INC
NEW YORK, NY, 10004
UnclaimedClaim this profile (free)
Prime contracting experience
18 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF | HHSN272201600011IUSAspending | $2,250,342 | Sep 28, 2026 | Sep 15, 2021 – Aug 31, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | HHSN272201800010I IAVI STORAGE OF GMP AND NON-GMP MATERIALS FOR NIAID BASE AWARD, CAN 8470038 FOR $435,313.50 CAN 8040917 FOR $435,313.50 TOTAL $870,627 | 75N93018D00010USAspending | $963,185 | Sep 11, 2026 | Sep 14, 2021 – Apr 30, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | 1800010I INTERNATIONAL AIDS VACCINE INITIATIVE TO V3 OBRA--2 BASE TASK ORDER FUNDING BIOD CAN 8470038 $642,953 | 75N93018D00010USAspending | $2,203,474 | Sep 2, 2026 | Feb 28, 2019 – Apr 30, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | NANOPARTICLE-BASED DEVELOPMENT FOR HIV-1 BIOMOLECULE DELIVERY | HHSN272201600011IUSAspending | $713,686 | Aug 21, 2026 | Aug 15, 2019 – Dec 15, 2021 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN | — | $95,592,504 | Jul 20, 2026 | Sep 30, 2021 – Dec 31, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS | 75N93022D00005USAspending | $8,398,301 | Jun 30, 2026 | Dec 1, 2021 – Aug 29, 2030 |
| Prime | Department of Health and Human Services National Institutes of Health | 1800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL | 75N93018D00010USAspending | $4,151,337 | May 13, 2026 | Aug 28, 2018 – May 14, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING | 75N93018D00010USAspending | $3,625,389 | Dec 19, 2025 | Sep 26, 2023 – Dec 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | COORDINATION AND TECHNICAL SUPPORT | HHSN272201600011IUSAspending | $256,138 | Mar 17, 2025 | Jul 15, 2020 – Jul 14, 2021 |
| Prime | Department of Defense Defense Threat Reduction Agency | ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM | — | $26,261,466 | Sep 16, 2024 | Oct 5, 2020 – Dec 4, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | ANTIGEN-ADJUVANT FORMULATION AND CHARACTERIZATION STUDIES | HHSN272201600011IUSAspending | $978,729 | Jun 25, 2024 | Aug 30, 2019 – Apr 16, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | PROCESS DEVELOPMENT FOR CELL CULTURE, UPSTREAM AND DOWNSTREAM PROCESS IN PRODUCTION OF HIV-1 BIOMOLECULES | HHSN272201600011IUSAspending | $1,707,175 | Jun 25, 2024 | Aug 15, 2019 – Apr 16, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | COORDINATION AND TECHNICAL SUPPORT | HHSN272201600011IUSAspending | $299,063 | Jun 25, 2024 | Jul 15, 2019 – Jul 14, 2020 |
| Prime | Department of Health and Human Services National Institutes of Health | PROCESS AND ASSAY DEVELOPMENT FOR CGMP PRODUCTION AND CHARACTERIZATION OF A VSV CANDIDATE | HHSN272201600011IUSAspending | $859,745 | Jan 5, 2024 | Aug 8, 2019 – Aug 30, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | 1800010I IAVI BASE AWARD $810,077 FY20 CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS (HBV) TOVM20V24VB 2 IID CAN 8470036 | 75N93018D00010USAspending | $1,098,404 | Sep 19, 2023 | Sep 22, 2020 – May 14, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF PURIFICATION OF HIV ENV PROTEINS WITH AN IMMUNOAFFINITY BASED PROCESS | HHSN272201600011IUSAspending | $1,572,742 | Jul 27, 2022 | Sep 20, 2016 – Jun 15, 2020 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF COORDINATION AND TECHNICAL SUPPORT | HHSN272201600011IUSAspending | $1,641,780 | Jul 27, 2022 | Jul 14, 2016 – Jul 14, 2019 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF FEASIBILITY ASSESSMENT OF HIV ENV PROTEIN ANTIGENS | HHSN272201600011IUSAspending | $432,452 | Jul 27, 2022 | Sep 14, 2017 – Oct 31, 2018 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.